Back to Search
Test Name REF LAB CULTURE YEAST WITH DIRECT FLUORESCENT KOH AND LIMITED SUSCEPTIY
Orderable CPT -
OVT 12300096097
Synonyms -
Result Test Name CULTURE YEAST W/DIRECT KOH
Laboratory QUEST LAB
Result Test Code 12375407925
Laboratory Test Name QUEST CULTURE YEAST WITH DIRECT FLUORESCENT KOH AND LIMITED SUSCEPTIBILITY
Reportable Test Name -
Result LOINC -
Collection Container ESWAB-WHITE CAP
Units -
Collection Requirements Preferred Specimen(s) Oral or vaginal swab collected in Amies Liquid Transport Swab Amies Gel Transport Swab Amies Liquid Elution Swab (ESwab) or equivalent Alternative Specimen(s) 10 mL unpreserved urine collected in a plastic sterile leak-proof container Rectal mucosa swab (without feces) Minimum Volume One swab specimen in transport medium 5 mL unpreserved urine Collection Instructions For surveillance testing - Composite skin of axilla/groin or nasal swab specimen
Container Temp Refrigerated (3)
Container Volume 5.000
Test Info Culture Yeast with Direct Fluorescent KOH and Limited Susceptibility - This test is used to identify a clinically significant yeast and determine its susceptibility to a limited set of antifungal agents. Potassium hydroxide (KOH) which dissolves human cells helps detect the presence of fungus. This test may be helpful in optimizing treatment for recurrent yeast infections. The susceptibility of a yeast isolate is measured by determining the minimum inhibitory concentration (MIC) which is the lowest drug concentration that prevents growth. An isolate can be categorized as susceptible intermediate susceptible-dose dependent or resistant by comparing the MIC of an isolate to established clinical breakpoints [1]. MIC interpretations are based on recently published guidelines from the Clinical and Laboratory Standards Institute (CLSI). When a clinical breakpoint for an antifungal agent is not established by CLSI guidelines only the MIC value is reported. For additional guidance please review current CLSI documents related to antifungal susceptibility testing of yeasts. Because treatment outcomes are influenced by many factors (eg drug pharmacokinetics pharmacodynamics and interactions; the patient's immune response; disease severity) a susceptible" or a "resistant" result does not ensure that a patient will or will not respond to a particular drug. Invasive yeast infections commonly caused by Candida and Cryptococcus are associated with significant morbidity and mortality especially in immunocompromised individuals [23]. Species of these organisms have unique virulence and antifungal susceptibility. A particular species can be resistant to some antifungal agents and susceptible to others. Therefore species identification and antifungal susceptibility testing can help guide treatment decisions for invasive infections [4]. Yeast susceptibility testing is useful when a yeast's identity does not reliably predict its susceptibility particularly when the identified yeast belongs to a species known to resist common antifungal agents [1]. The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings. References 1. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th ed. CLSI guideline M27. Clinical and Laboratory Standards Institute; 2017. 2. Invasive candidiasis statistics. Centers for Disease Control and Prevention. Updated August 24 2021. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html 3. C. neoformans Infection Statistics. Centers for Disease Control and Prevention. Updated May 26 2020. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/cryptococcosis-neoformans/statistics.html 4. Pappas PG et al. Clin Infect Dis. 2016;62(4):e1-e50."
Shipping Instructions Transport Container ESwab Liquid Amies (red-cap) or gel Amies (blue-cap) Urine: Sterile leak-proof container Transport Temperature Preserved swab specimen: Room temperature Unpreserved urine: Refrigerated (cold packs) Specimen Stability Preserved swab specimens Room temperature: 72 hours Refrigerated: 72 hours Frozen: Unacceptable Unpreserved urine Room temperature: Unacceptable Refrigerated: 48 hours Frozen: Unacceptable Reject Criteria Stool Sputum Blood Bone marrow Hair Nails Specimen received frozen Specimen in formalin Serum Body fluid Preserved urine Tissue
Result Test Name QUEST CULTURE
Laboratory QUEST LAB
Result Test Code 12375407926
Laboratory Test Name QUEST CULTURE YEAST WITH DIRECT FLUORESCENT KOH AND LIMITED SUSCEPTIBILITY
Reportable Test Name -
Result LOINC 18482-0
Collection Container ESWAB-WHITE CAP
Units -
Collection Requirements Preferred Specimen(s) Oral or vaginal swab collected in Amies Liquid Transport Swab Amies Gel Transport Swab Amies Liquid Elution Swab (ESwab) or equivalent Alternative Specimen(s) 10 mL unpreserved urine collected in a plastic sterile leak-proof container Rectal mucosa swab (without feces) Minimum Volume One swab specimen in transport medium 5 mL unpreserved urine Collection Instructions For surveillance testing - Composite skin of axilla/groin or nasal swab specimen
Container Temp Room Temperature (1)
Container Volume 5.000
Test Info Culture Yeast with Direct Fluorescent KOH and Limited Susceptibility - This test is used to identify a clinically significant yeast and determine its susceptibility to a limited set of antifungal agents. Potassium hydroxide (KOH) which dissolves human cells helps detect the presence of fungus. This test may be helpful in optimizing treatment for recurrent yeast infections. The susceptibility of a yeast isolate is measured by determining the minimum inhibitory concentration (MIC) which is the lowest drug concentration that prevents growth. An isolate can be categorized as susceptible intermediate susceptible-dose dependent or resistant by comparing the MIC of an isolate to established clinical breakpoints [1]. MIC interpretations are based on recently published guidelines from the Clinical and Laboratory Standards Institute (CLSI). When a clinical breakpoint for an antifungal agent is not established by CLSI guidelines only the MIC value is reported. For additional guidance please review current CLSI documents related to antifungal susceptibility testing of yeasts. Because treatment outcomes are influenced by many factors (eg drug pharmacokinetics pharmacodynamics and interactions; the patient's immune response; disease severity) a susceptible" or a "resistant" result does not ensure that a patient will or will not respond to a particular drug. Invasive yeast infections commonly caused by Candida and Cryptococcus are associated with significant morbidity and mortality especially in immunocompromised individuals [23]. Species of these organisms have unique virulence and antifungal susceptibility. A particular species can be resistant to some antifungal agents and susceptible to others. Therefore species identification and antifungal susceptibility testing can help guide treatment decisions for invasive infections [4]. Yeast susceptibility testing is useful when a yeast's identity does not reliably predict its susceptibility particularly when the identified yeast belongs to a species known to resist common antifungal agents [1]. The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings. References 1. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th ed. CLSI guideline M27. Clinical and Laboratory Standards Institute; 2017. 2. Invasive candidiasis statistics. Centers for Disease Control and Prevention. Updated August 24 2021. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html 3. C. neoformans Infection Statistics. Centers for Disease Control and Prevention. Updated May 26 2020. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/cryptococcosis-neoformans/statistics.html 4. Pappas PG et al. Clin Infect Dis. 2016;62(4):e1-e50."
Shipping Instructions Transport Container ESwab Liquid Amies (red-cap) or gel Amies (blue-cap) Urine: Sterile leak-proof container Transport Temperature Preserved swab specimen: Room temperature Unpreserved urine: Refrigerated (cold packs) Specimen Stability Preserved swab specimens Room temperature: 72 hours Refrigerated: 72 hours Frozen: Unacceptable Unpreserved urine Room temperature: Unacceptable Refrigerated: 48 hours Frozen: Unacceptable Reject Criteria Stool Sputum Blood Bone marrow Hair Nails Specimen received frozen Specimen in formalin Serum Body fluid Preserved urine Tissue
Result Test Name CULTURE YEAST W/DIRECT KOH
Laboratory QUEST LAB
Result Test Code 12375407925
Laboratory Test Name QUEST CULTURE YEAST WITH DIRECT FLUORESCENT KOH AND LIMITED SUSCEPTIBILITY
Reportable Test Name -
Result LOINC -
Collection Container ESWAB-WHITE CAP
Units -
Collection Requirements Preferred Specimen(s) Oral or vaginal swab collected in Amies Liquid Transport Swab Amies Gel Transport Swab Amies Liquid Elution Swab (ESwab) or equivalent Alternative Specimen(s) 10 mL unpreserved urine collected in a plastic sterile leak-proof container Rectal mucosa swab (without feces) Minimum Volume One swab specimen in transport medium 5 mL unpreserved urine Collection Instructions For surveillance testing - Composite skin of axilla/groin or nasal swab specimen
Container Temp Refrigerated (3)
Container Volume -
Test Info Culture Yeast with Direct Fluorescent KOH and Limited Susceptibility - This test is used to identify a clinically significant yeast and determine its susceptibility to a limited set of antifungal agents. Potassium hydroxide (KOH) which dissolves human cells helps detect the presence of fungus. This test may be helpful in optimizing treatment for recurrent yeast infections. The susceptibility of a yeast isolate is measured by determining the minimum inhibitory concentration (MIC) which is the lowest drug concentration that prevents growth. An isolate can be categorized as susceptible intermediate susceptible-dose dependent or resistant by comparing the MIC of an isolate to established clinical breakpoints [1]. MIC interpretations are based on recently published guidelines from the Clinical and Laboratory Standards Institute (CLSI). When a clinical breakpoint for an antifungal agent is not established by CLSI guidelines only the MIC value is reported. For additional guidance please review current CLSI documents related to antifungal susceptibility testing of yeasts. Because treatment outcomes are influenced by many factors (eg drug pharmacokinetics pharmacodynamics and interactions; the patient's immune response; disease severity) a susceptible" or a "resistant" result does not ensure that a patient will or will not respond to a particular drug. Invasive yeast infections commonly caused by Candida and Cryptococcus are associated with significant morbidity and mortality especially in immunocompromised individuals [23]. Species of these organisms have unique virulence and antifungal susceptibility. A particular species can be resistant to some antifungal agents and susceptible to others. Therefore species identification and antifungal susceptibility testing can help guide treatment decisions for invasive infections [4]. Yeast susceptibility testing is useful when a yeast's identity does not reliably predict its susceptibility particularly when the identified yeast belongs to a species known to resist common antifungal agents [1]. The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings. References 1. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th ed. CLSI guideline M27. Clinical and Laboratory Standards Institute; 2017. 2. Invasive candidiasis statistics. Centers for Disease Control and Prevention. Updated August 24 2021. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html 3. C. neoformans Infection Statistics. Centers for Disease Control and Prevention. Updated May 26 2020. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/cryptococcosis-neoformans/statistics.html 4. Pappas PG et al. Clin Infect Dis. 2016;62(4):e1-e50."
Shipping Instructions Transport Container ESwab Liquid Amies (red-cap) or gel Amies (blue-cap) Urine: Sterile leak-proof container Transport Temperature Preserved swab specimen: Room temperature Unpreserved urine: Refrigerated (cold packs) Specimen Stability Preserved swab specimens Room temperature: 72 hours Refrigerated: 72 hours Frozen: Unacceptable Unpreserved urine Room temperature: Unacceptable Refrigerated: 48 hours Frozen: Unacceptable Reject Criteria Stool Sputum Blood Bone marrow Hair Nails Specimen received frozen Specimen in formalin Serum Body fluid Preserved urine Tissue
Result Test Name QUEST CULTURE
Laboratory QUEST LAB
Result Test Code 12375407926
Laboratory Test Name QUEST CULTURE YEAST WITH DIRECT FLUORESCENT KOH AND LIMITED SUSCEPTIBILITY
Reportable Test Name -
Result LOINC 18482-0
Collection Container ESWAB-WHITE CAP
Units -
Collection Requirements Preferred Specimen(s) Oral or vaginal swab collected in Amies Liquid Transport Swab Amies Gel Transport Swab Amies Liquid Elution Swab (ESwab) or equivalent Alternative Specimen(s) 10 mL unpreserved urine collected in a plastic sterile leak-proof container Rectal mucosa swab (without feces) Minimum Volume One swab specimen in transport medium 5 mL unpreserved urine Collection Instructions For surveillance testing - Composite skin of axilla/groin or nasal swab specimen
Container Temp Room Temperature (1)
Container Volume -
Test Info Culture Yeast with Direct Fluorescent KOH and Limited Susceptibility - This test is used to identify a clinically significant yeast and determine its susceptibility to a limited set of antifungal agents. Potassium hydroxide (KOH) which dissolves human cells helps detect the presence of fungus. This test may be helpful in optimizing treatment for recurrent yeast infections. The susceptibility of a yeast isolate is measured by determining the minimum inhibitory concentration (MIC) which is the lowest drug concentration that prevents growth. An isolate can be categorized as susceptible intermediate susceptible-dose dependent or resistant by comparing the MIC of an isolate to established clinical breakpoints [1]. MIC interpretations are based on recently published guidelines from the Clinical and Laboratory Standards Institute (CLSI). When a clinical breakpoint for an antifungal agent is not established by CLSI guidelines only the MIC value is reported. For additional guidance please review current CLSI documents related to antifungal susceptibility testing of yeasts. Because treatment outcomes are influenced by many factors (eg drug pharmacokinetics pharmacodynamics and interactions; the patient's immune response; disease severity) a susceptible" or a "resistant" result does not ensure that a patient will or will not respond to a particular drug. Invasive yeast infections commonly caused by Candida and Cryptococcus are associated with significant morbidity and mortality especially in immunocompromised individuals [23]. Species of these organisms have unique virulence and antifungal susceptibility. A particular species can be resistant to some antifungal agents and susceptible to others. Therefore species identification and antifungal susceptibility testing can help guide treatment decisions for invasive infections [4]. Yeast susceptibility testing is useful when a yeast's identity does not reliably predict its susceptibility particularly when the identified yeast belongs to a species known to resist common antifungal agents [1]. The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings. References 1. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th ed. CLSI guideline M27. Clinical and Laboratory Standards Institute; 2017. 2. Invasive candidiasis statistics. Centers for Disease Control and Prevention. Updated August 24 2021. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html 3. C. neoformans Infection Statistics. Centers for Disease Control and Prevention. Updated May 26 2020. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/cryptococcosis-neoformans/statistics.html 4. Pappas PG et al. Clin Infect Dis. 2016;62(4):e1-e50."
Shipping Instructions Transport Container ESwab Liquid Amies (red-cap) or gel Amies (blue-cap) Urine: Sterile leak-proof container Transport Temperature Preserved swab specimen: Room temperature Unpreserved urine: Refrigerated (cold packs) Specimen Stability Preserved swab specimens Room temperature: 72 hours Refrigerated: 72 hours Frozen: Unacceptable Unpreserved urine Room temperature: Unacceptable Refrigerated: 48 hours Frozen: Unacceptable Reject Criteria Stool Sputum Blood Bone marrow Hair Nails Specimen received frozen Specimen in formalin Serum Body fluid Preserved urine Tissue
Result Test Name CULTURE YEAST W/DIRECT KOH
Laboratory QUEST LAB
Result Test Code 12375407925
Laboratory Test Name QUEST CULTURE YEAST WITH DIRECT FLUORESCENT KOH AND LIMITED SUSCEPTIBILITY
Reportable Test Name -
Result LOINC -
Collection Container ESWAB-WHITE CAP
Units -
Collection Requirements Preferred Specimen(s) Oral or vaginal swab collected in Amies Liquid Transport Swab Amies Gel Transport Swab Amies Liquid Elution Swab (ESwab) or equivalent Alternative Specimen(s) 10 mL unpreserved urine collected in a plastic sterile leak-proof container Rectal mucosa swab (without feces) Minimum Volume One swab specimen in transport medium 5 mL unpreserved urine Collection Instructions For surveillance testing - Composite skin of axilla/groin or nasal swab specimen
Container Temp Room Temperature (1)
Container Volume 5.000
Test Info Culture Yeast with Direct Fluorescent KOH and Limited Susceptibility - This test is used to identify a clinically significant yeast and determine its susceptibility to a limited set of antifungal agents. Potassium hydroxide (KOH) which dissolves human cells helps detect the presence of fungus. This test may be helpful in optimizing treatment for recurrent yeast infections. The susceptibility of a yeast isolate is measured by determining the minimum inhibitory concentration (MIC) which is the lowest drug concentration that prevents growth. An isolate can be categorized as susceptible intermediate susceptible-dose dependent or resistant by comparing the MIC of an isolate to established clinical breakpoints [1]. MIC interpretations are based on recently published guidelines from the Clinical and Laboratory Standards Institute (CLSI). When a clinical breakpoint for an antifungal agent is not established by CLSI guidelines only the MIC value is reported. For additional guidance please review current CLSI documents related to antifungal susceptibility testing of yeasts. Because treatment outcomes are influenced by many factors (eg drug pharmacokinetics pharmacodynamics and interactions; the patient's immune response; disease severity) a susceptible" or a "resistant" result does not ensure that a patient will or will not respond to a particular drug. Invasive yeast infections commonly caused by Candida and Cryptococcus are associated with significant morbidity and mortality especially in immunocompromised individuals [23]. Species of these organisms have unique virulence and antifungal susceptibility. A particular species can be resistant to some antifungal agents and susceptible to others. Therefore species identification and antifungal susceptibility testing can help guide treatment decisions for invasive infections [4]. Yeast susceptibility testing is useful when a yeast's identity does not reliably predict its susceptibility particularly when the identified yeast belongs to a species known to resist common antifungal agents [1]. The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings. References 1. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th ed. CLSI guideline M27. Clinical and Laboratory Standards Institute; 2017. 2. Invasive candidiasis statistics. Centers for Disease Control and Prevention. Updated August 24 2021. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html 3. C. neoformans Infection Statistics. Centers for Disease Control and Prevention. Updated May 26 2020. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/cryptococcosis-neoformans/statistics.html 4. Pappas PG et al. Clin Infect Dis. 2016;62(4):e1-e50."
Shipping Instructions Transport Container ESwab Liquid Amies (red-cap) or gel Amies (blue-cap) Urine: Sterile leak-proof container Transport Temperature Preserved swab specimen: Room temperature Unpreserved urine: Refrigerated (cold packs) Specimen Stability Preserved swab specimens Room temperature: 72 hours Refrigerated: 72 hours Frozen: Unacceptable Unpreserved urine Room temperature: Unacceptable Refrigerated: 48 hours Frozen: Unacceptable Reject Criteria Stool Sputum Blood Bone marrow Hair Nails Specimen received frozen Specimen in formalin Serum Body fluid Preserved urine Tissue
Result Test Name QUEST CULTURE
Laboratory QUEST LAB
Result Test Code 12375407926
Laboratory Test Name QUEST CULTURE YEAST WITH DIRECT FLUORESCENT KOH AND LIMITED SUSCEPTIBILITY
Reportable Test Name -
Result LOINC 18482-0
Collection Container ESWAB-WHITE CAP
Units -
Collection Requirements Preferred Specimen(s) Oral or vaginal swab collected in Amies Liquid Transport Swab Amies Gel Transport Swab Amies Liquid Elution Swab (ESwab) or equivalent Alternative Specimen(s) 10 mL unpreserved urine collected in a plastic sterile leak-proof container Rectal mucosa swab (without feces) Minimum Volume One swab specimen in transport medium 5 mL unpreserved urine Collection Instructions For surveillance testing - Composite skin of axilla/groin or nasal swab specimen
Container Temp Refrigerated (3)
Container Volume 5.000
Test Info Culture Yeast with Direct Fluorescent KOH and Limited Susceptibility - This test is used to identify a clinically significant yeast and determine its susceptibility to a limited set of antifungal agents. Potassium hydroxide (KOH) which dissolves human cells helps detect the presence of fungus. This test may be helpful in optimizing treatment for recurrent yeast infections. The susceptibility of a yeast isolate is measured by determining the minimum inhibitory concentration (MIC) which is the lowest drug concentration that prevents growth. An isolate can be categorized as susceptible intermediate susceptible-dose dependent or resistant by comparing the MIC of an isolate to established clinical breakpoints [1]. MIC interpretations are based on recently published guidelines from the Clinical and Laboratory Standards Institute (CLSI). When a clinical breakpoint for an antifungal agent is not established by CLSI guidelines only the MIC value is reported. For additional guidance please review current CLSI documents related to antifungal susceptibility testing of yeasts. Because treatment outcomes are influenced by many factors (eg drug pharmacokinetics pharmacodynamics and interactions; the patient's immune response; disease severity) a susceptible" or a "resistant" result does not ensure that a patient will or will not respond to a particular drug. Invasive yeast infections commonly caused by Candida and Cryptococcus are associated with significant morbidity and mortality especially in immunocompromised individuals [23]. Species of these organisms have unique virulence and antifungal susceptibility. A particular species can be resistant to some antifungal agents and susceptible to others. Therefore species identification and antifungal susceptibility testing can help guide treatment decisions for invasive infections [4]. Yeast susceptibility testing is useful when a yeast's identity does not reliably predict its susceptibility particularly when the identified yeast belongs to a species known to resist common antifungal agents [1]. The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings. References 1. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th ed. CLSI guideline M27. Clinical and Laboratory Standards Institute; 2017. 2. Invasive candidiasis statistics. Centers for Disease Control and Prevention. Updated August 24 2021. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html 3. C. neoformans Infection Statistics. Centers for Disease Control and Prevention. Updated May 26 2020. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/cryptococcosis-neoformans/statistics.html 4. Pappas PG et al. Clin Infect Dis. 2016;62(4):e1-e50."
Shipping Instructions Transport Container ESwab Liquid Amies (red-cap) or gel Amies (blue-cap) Urine: Sterile leak-proof container Transport Temperature Preserved swab specimen: Room temperature Unpreserved urine: Refrigerated (cold packs) Specimen Stability Preserved swab specimens Room temperature: 72 hours Refrigerated: 72 hours Frozen: Unacceptable Unpreserved urine Room temperature: Unacceptable Refrigerated: 48 hours Frozen: Unacceptable Reject Criteria Stool Sputum Blood Bone marrow Hair Nails Specimen received frozen Specimen in formalin Serum Body fluid Preserved urine Tissue
Result Test Name CULTURE YEAST W/DIRECT KOH
Laboratory QUEST LAB
Result Test Code 12375407925
Laboratory Test Name QUEST CULTURE YEAST WITH DIRECT FLUORESCENT KOH AND LIMITED SUSCEPTIBILITY
Reportable Test Name -
Result LOINC -
Collection Container ESWAB-WHITE CAP
Units -
Collection Requirements Preferred Specimen(s) Oral or vaginal swab collected in Amies Liquid Transport Swab Amies Gel Transport Swab Amies Liquid Elution Swab (ESwab) or equivalent Alternative Specimen(s) 10 mL unpreserved urine collected in a plastic sterile leak-proof container Rectal mucosa swab (without feces) Minimum Volume One swab specimen in transport medium 5 mL unpreserved urine Collection Instructions For surveillance testing - Composite skin of axilla/groin or nasal swab specimen
Container Temp Room Temperature (1)
Container Volume -
Test Info Culture Yeast with Direct Fluorescent KOH and Limited Susceptibility - This test is used to identify a clinically significant yeast and determine its susceptibility to a limited set of antifungal agents. Potassium hydroxide (KOH) which dissolves human cells helps detect the presence of fungus. This test may be helpful in optimizing treatment for recurrent yeast infections. The susceptibility of a yeast isolate is measured by determining the minimum inhibitory concentration (MIC) which is the lowest drug concentration that prevents growth. An isolate can be categorized as susceptible intermediate susceptible-dose dependent or resistant by comparing the MIC of an isolate to established clinical breakpoints [1]. MIC interpretations are based on recently published guidelines from the Clinical and Laboratory Standards Institute (CLSI). When a clinical breakpoint for an antifungal agent is not established by CLSI guidelines only the MIC value is reported. For additional guidance please review current CLSI documents related to antifungal susceptibility testing of yeasts. Because treatment outcomes are influenced by many factors (eg drug pharmacokinetics pharmacodynamics and interactions; the patient's immune response; disease severity) a susceptible" or a "resistant" result does not ensure that a patient will or will not respond to a particular drug. Invasive yeast infections commonly caused by Candida and Cryptococcus are associated with significant morbidity and mortality especially in immunocompromised individuals [23]. Species of these organisms have unique virulence and antifungal susceptibility. A particular species can be resistant to some antifungal agents and susceptible to others. Therefore species identification and antifungal susceptibility testing can help guide treatment decisions for invasive infections [4]. Yeast susceptibility testing is useful when a yeast's identity does not reliably predict its susceptibility particularly when the identified yeast belongs to a species known to resist common antifungal agents [1]. The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings. References 1. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th ed. CLSI guideline M27. Clinical and Laboratory Standards Institute; 2017. 2. Invasive candidiasis statistics. Centers for Disease Control and Prevention. Updated August 24 2021. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html 3. C. neoformans Infection Statistics. Centers for Disease Control and Prevention. Updated May 26 2020. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/cryptococcosis-neoformans/statistics.html 4. Pappas PG et al. Clin Infect Dis. 2016;62(4):e1-e50."
Shipping Instructions Transport Container ESwab Liquid Amies (red-cap) or gel Amies (blue-cap) Urine: Sterile leak-proof container Transport Temperature Preserved swab specimen: Room temperature Unpreserved urine: Refrigerated (cold packs) Specimen Stability Preserved swab specimens Room temperature: 72 hours Refrigerated: 72 hours Frozen: Unacceptable Unpreserved urine Room temperature: Unacceptable Refrigerated: 48 hours Frozen: Unacceptable Reject Criteria Stool Sputum Blood Bone marrow Hair Nails Specimen received frozen Specimen in formalin Serum Body fluid Preserved urine Tissue
Result Test Name QUEST CULTURE
Laboratory QUEST LAB
Result Test Code 12375407926
Laboratory Test Name QUEST CULTURE YEAST WITH DIRECT FLUORESCENT KOH AND LIMITED SUSCEPTIBILITY
Reportable Test Name -
Result LOINC 18482-0
Collection Container ESWAB-WHITE CAP
Units -
Collection Requirements Preferred Specimen(s) Oral or vaginal swab collected in Amies Liquid Transport Swab Amies Gel Transport Swab Amies Liquid Elution Swab (ESwab) or equivalent Alternative Specimen(s) 10 mL unpreserved urine collected in a plastic sterile leak-proof container Rectal mucosa swab (without feces) Minimum Volume One swab specimen in transport medium 5 mL unpreserved urine Collection Instructions For surveillance testing - Composite skin of axilla/groin or nasal swab specimen
Container Temp Refrigerated (3)
Container Volume -
Test Info Culture Yeast with Direct Fluorescent KOH and Limited Susceptibility - This test is used to identify a clinically significant yeast and determine its susceptibility to a limited set of antifungal agents. Potassium hydroxide (KOH) which dissolves human cells helps detect the presence of fungus. This test may be helpful in optimizing treatment for recurrent yeast infections. The susceptibility of a yeast isolate is measured by determining the minimum inhibitory concentration (MIC) which is the lowest drug concentration that prevents growth. An isolate can be categorized as susceptible intermediate susceptible-dose dependent or resistant by comparing the MIC of an isolate to established clinical breakpoints [1]. MIC interpretations are based on recently published guidelines from the Clinical and Laboratory Standards Institute (CLSI). When a clinical breakpoint for an antifungal agent is not established by CLSI guidelines only the MIC value is reported. For additional guidance please review current CLSI documents related to antifungal susceptibility testing of yeasts. Because treatment outcomes are influenced by many factors (eg drug pharmacokinetics pharmacodynamics and interactions; the patient's immune response; disease severity) a susceptible" or a "resistant" result does not ensure that a patient will or will not respond to a particular drug. Invasive yeast infections commonly caused by Candida and Cryptococcus are associated with significant morbidity and mortality especially in immunocompromised individuals [23]. Species of these organisms have unique virulence and antifungal susceptibility. A particular species can be resistant to some antifungal agents and susceptible to others. Therefore species identification and antifungal susceptibility testing can help guide treatment decisions for invasive infections [4]. Yeast susceptibility testing is useful when a yeast's identity does not reliably predict its susceptibility particularly when the identified yeast belongs to a species known to resist common antifungal agents [1]. The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings. References 1. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th ed. CLSI guideline M27. Clinical and Laboratory Standards Institute; 2017. 2. Invasive candidiasis statistics. Centers for Disease Control and Prevention. Updated August 24 2021. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html 3. C. neoformans Infection Statistics. Centers for Disease Control and Prevention. Updated May 26 2020. Accessed February 7 2022. https://www.cdc.gov/fungal/diseases/cryptococcosis-neoformans/statistics.html 4. Pappas PG et al. Clin Infect Dis. 2016;62(4):e1-e50."
Shipping Instructions Transport Container ESwab Liquid Amies (red-cap) or gel Amies (blue-cap) Urine: Sterile leak-proof container Transport Temperature Preserved swab specimen: Room temperature Unpreserved urine: Refrigerated (cold packs) Specimen Stability Preserved swab specimens Room temperature: 72 hours Refrigerated: 72 hours Frozen: Unacceptable Unpreserved urine Room temperature: Unacceptable Refrigerated: 48 hours Frozen: Unacceptable Reject Criteria Stool Sputum Blood Bone marrow Hair Nails Specimen received frozen Specimen in formalin Serum Body fluid Preserved urine Tissue